253 related articles for article (PubMed ID: 19542537)
41. Pharmacological enhancement of retinoid-related orphan receptor α function mitigates spinocerebellar ataxia type 3 pathology.
Watanave M; Hoshino C; Konno A; Fukuzaki Y; Matsuzaki Y; Ishitani T; Hirai H
Neurobiol Dis; 2019 Jan; 121():263-273. PubMed ID: 30343032
[TBL] [Abstract][Full Text] [Related]
42. Differential recruitment of UBQLN2 to nuclear inclusions in the polyglutamine diseases HD and SCA3.
Zeng L; Wang B; Merillat SA; Minakawa EN; Perkins MD; Ramani B; Tallaksen-Greene SJ; Costa MDC; Albin RL; Paulson HL
Neurobiol Dis; 2015 Oct; 82():281-288. PubMed ID: 26141599
[TBL] [Abstract][Full Text] [Related]
43. Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machado-Joseph disease.
Nascimento-Ferreira I; Nóbrega C; Vasconcelos-Ferreira A; Onofre I; Albuquerque D; Aveleira C; Hirai H; Déglon N; Pereira de Almeida L
Brain; 2013 Jul; 136(Pt 7):2173-88. PubMed ID: 23801739
[TBL] [Abstract][Full Text] [Related]
44. Nuclear aggregation of polyglutamine-expanded ataxin-3: fragments escape the cytoplasmic quality control.
Breuer P; Haacke A; Evert BO; Wüllner U
J Biol Chem; 2010 Feb; 285(9):6532-7. PubMed ID: 20064935
[TBL] [Abstract][Full Text] [Related]
45. Functional interactions as a survival strategy against abnormal aggregation.
Masino L; Nicastro G; Calder L; Vendruscolo M; Pastore A
FASEB J; 2011 Jan; 25(1):45-54. PubMed ID: 20810784
[TBL] [Abstract][Full Text] [Related]
46. Increased transcript diversity: novel splicing variants of Machado-Joseph disease gene (ATXN3).
Bettencourt C; Santos C; Montiel R; Costa Mdo C; Cruz-Morales P; Santos LR; Simões N; Kay T; Vasconcelos J; Maciel P; Lima M
Neurogenetics; 2010 May; 11(2):193-202. PubMed ID: 19714377
[TBL] [Abstract][Full Text] [Related]
47. Understanding the role of the Josephin domain in the PolyUb binding and cleavage properties of ataxin-3.
Nicastro G; Todi SV; Karaca E; Bonvin AM; Paulson HL; Pastore A
PLoS One; 2010 Aug; 5(8):e12430. PubMed ID: 20865150
[TBL] [Abstract][Full Text] [Related]
48. Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3.
Boy J; Schmidt T; Wolburg H; Mack A; Nuber S; Böttcher M; Schmitt I; Holzmann C; Zimmermann F; Servadio A; Riess O
Hum Mol Genet; 2009 Nov; 18(22):4282-95. PubMed ID: 19666958
[TBL] [Abstract][Full Text] [Related]
49. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease.
Alves S; Régulier E; Nascimento-Ferreira I; Hassig R; Dufour N; Koeppen A; Carvalho AL; Simões S; de Lima MC; Brouillet E; Gould VC; Déglon N; de Almeida LP
Hum Mol Genet; 2008 Jul; 17(14):2071-83. PubMed ID: 18385100
[TBL] [Abstract][Full Text] [Related]
50. Karyopherin α-3 is a key protein in the pathogenesis of spinocerebellar ataxia type 3 controlling the nuclear localization of ataxin-3.
Sowa AS; Martin E; Martins IM; Schmidt J; Depping R; Weber JJ; Rother F; Hartmann E; Bader M; Riess O; Tricoire H; Schmidt T
Proc Natl Acad Sci U S A; 2018 Mar; 115(11):E2624-E2633. PubMed ID: 29476013
[TBL] [Abstract][Full Text] [Related]
51. Decreased antioxidant enzyme activity and increased mitochondrial DNA damage in cellular models of Machado-Joseph disease.
Yu YC; Kuo CL; Cheng WL; Liu CS; Hsieh M
J Neurosci Res; 2009 Jun; 87(8):1884-91. PubMed ID: 19185026
[TBL] [Abstract][Full Text] [Related]
52. Homozygosity enhances severity in spinocerebellar ataxia type 3.
Carvalho DR; La Rocque-Ferreira A; Rizzo IM; Imamura EU; Speck-Martins CE
Pediatr Neurol; 2008 Apr; 38(4):296-9. PubMed ID: 18358414
[TBL] [Abstract][Full Text] [Related]
53. A knockin mouse model of spinocerebellar ataxia type 3 exhibits prominent aggregate pathology and aberrant splicing of the disease gene transcript.
Ramani B; Harris GM; Huang R; Seki T; Murphy GG; Costa Mdo C; Fischer S; Saunders TL; Xia G; McEachin RC; Paulson HL
Hum Mol Genet; 2015 Mar; 24(5):1211-24. PubMed ID: 25320121
[TBL] [Abstract][Full Text] [Related]
54. Absence of ataxin-3 leads to cytoskeletal disorganization and increased cell death.
Rodrigues AJ; do Carmo Costa M; Silva TL; Ferreira D; Bajanca F; Logarinho E; Maciel P
Biochim Biophys Acta; 2010 Oct; 1803(10):1154-63. PubMed ID: 20637808
[TBL] [Abstract][Full Text] [Related]
55. Preventing Ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3.
Jung J; Xu K; Lessing D; Bonini NM
Hum Mol Genet; 2009 Dec; 18(24):4843-52. PubMed ID: 19783548
[TBL] [Abstract][Full Text] [Related]
56. Mouse ataxin-3 functional knock-out model.
Switonski PM; Fiszer A; Kazmierska K; Kurpisz M; Krzyzosiak WJ; Figiel M
Neuromolecular Med; 2011 Mar; 13(1):54-65. PubMed ID: 20945165
[TBL] [Abstract][Full Text] [Related]
57. The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability.
Durcan TM; Kontogiannea M; Thorarinsdottir T; Fallon L; Williams AJ; Djarmati A; Fantaneanu T; Paulson HL; Fon EA
Hum Mol Genet; 2011 Jan; 20(1):141-54. PubMed ID: 20940148
[TBL] [Abstract][Full Text] [Related]
58. CRISPR/Cas9-Targeted Deletion of Polyglutamine in Spinocerebellar Ataxia Type 3-Derived Induced Pluripotent Stem Cells.
Ouyang S; Xie Y; Xiong Z; Yang Y; Xian Y; Ou Z; Song B; Chen Y; Xie Y; Li H; Sun X
Stem Cells Dev; 2018 Jun; 27(11):756-770. PubMed ID: 29661116
[TBL] [Abstract][Full Text] [Related]
59. SUMO-1 modification on K166 of polyQ-expanded ataxin-3 strengthens its stability and increases its cytotoxicity.
Zhou YF; Liao SS; Luo YY; Tang JG; Wang JL; Lei LF; Chi JW; Du J; Jiang H; Xia K; Tang BS; Shen L
PLoS One; 2013; 8(1):e54214. PubMed ID: 23382880
[TBL] [Abstract][Full Text] [Related]
60. Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism.
Warrick JM; Morabito LM; Bilen J; Gordesky-Gold B; Faust LZ; Paulson HL; Bonini NM
Mol Cell; 2005 Apr; 18(1):37-48. PubMed ID: 15808507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
